New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
SOLITARY PLASMACYTOMA OF BONE - TREATMENT, PROGRESSION, AND SURVIVAL
À¶Ý®ÊÓƵ
SOLITARY PLASMACYTOMA OF BONE - TREATMENT, PROGRESSION, AND SURVIVAL JOURNAL OF CLINICAL ONCOLOGY CHAK, L. Y., Cox, R. S., Bostwick, D. G., Hoppe, R. T. 1987; 5 (11): 1811-1815Abstract
Twenty patients with solitary plasmacytoma of bone were treated by radiation therapy. Local control was achieved in 19 and most patients developed systemic myeloma. To evaluate disease progression, 65 patients, including 45 from published series, were analyzed. Younger patients seemed less likely to progress (P = .06), but other clinical characteristics including site of involvement and paraprotein status did not influence progression. After dissemination, patients had a clinical course similar to patients with stage I myeloma, with a median survival of 47 months. Overall, patients with solitary plasmacytoma of bone had an indolent course of disease, with a median survival of 10.7 years and a 5-, 10-, and 20-year survival of 75%, 52%, and 37%, respectively.
View details for
View details for